19263-21-9

Basic information

• Product Name: BROMOETHYLTRIFLATE
• Synonyms: BROMOETHYLTRIFLATE;2-BroMo-ethyl tosylate;Ethanol, 2-bromo-, 1-(4-methylbenzenesulfonate)
• CAS NO: 19263-21-9
• Molecular Formula: C₉H₁₁BrO₃S
• Molecular Weight: 257.026
• Mol File: 19263-21-9.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BROMOETHYLTRIFLATE(CAS DataBase Reference)
• NIST Chemistry Reference: BROMOETHYLTRIFLATE(19263-21-9)
• EPA Substance Registry System: BROMOETHYLTRIFLATE(19263-21-9)

Safety Data

• Hazardous Substances Data: 19263-21-9(Hazardous Substances Data)

Usage

Description

Bromoethyltriflate, with the molecular formula C4H5BrO3, is a colorless to pale yellow liquid chemical compound known for its high reactivity. It functions as a potent alkylating agent, capable of transferring its ethyl group to other molecules, which makes it instrumental in the synthesis of pharmaceuticals and a variety of organic compounds. Additionally, it serves as a reagent for preparing functionalized compounds and can be a precursor in the synthesis of other alkylating agents. Due to its high toxicity and potential to cause severe skin and eye irritation, careful handling is essential.

Uses

Used in Pharmaceutical Synthesis:
Bromoethyltriflate is used as a reagent in the synthesis of pharmaceuticals for its ability to transfer ethyl groups, which is crucial in creating specific molecular structures required for drug development.
Used in Organic Synthesis:
In the realm of organic synthesis, bromoethyltriflate is utilized as a reagent for the preparation of various functionalized compounds, contributing to the creation of new organic molecules with unique properties.
Used in Synthesis of Alkylating Agents:
Bromoethyltriflate also serves as a potential precursor in the synthesis of alkylating agents, which are important in various chemical reactions and applications.
Used in Research and Development:
Due to its reactivity and alkylating properties, bromoethyltriflate is used in research and development settings to explore new chemical reactions and to develop innovative synthetic pathways for complex organic molecules.

Upstream product

• 74-85-1 ethene 
• 104-15-4 toluene-4-sulfonic acid 
• 98-59-9 p-toluenesulfonyl chloride 
• 540-51-2 2-bromoethanol 
• 7182-86-7 tetrabutylammonium p-toluenesulfonate 
• 107-04-0 1-Bromo-2-chloroethane 
• 80-48-8 methyl p-toluene sulfonate 
• 99142-43-5 N-(2-bromoethyl)-N-nitroso-4-methylbenzenesulfonamide 

Downstream Products

• 111453-02-2 toluene-4-sulfonic acid-[N-(2-bromo-ethyl)-4-(4-nitro-phenylsulfanyl)-anilide] 
• 762-49-2 2-fluoroethyl bromide 
• 17046-84-3 1,4-bis-(toluene-4-sulfonyl)-piperazine 
• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 5460-83-3 2-(1,3-dioxoisoindolin-2-yl)ethyl 4-methylbenzenesulfonate 
• 52191-15-8 4-(2-bromoethyloxy)benzaldehyde 
• 113426-12-3 [(18)F]-2-fluoroethyltosylate 
• 85725-77-5 1-bromo-2-[¹⁸F]fluoroethane 
• 80-40-0 ethyl ester of p-toluenesulfonic acid 
• 1613033-36-5 methyl 2-(2-bromoethyloxybenzyl)-4-(cis-3a,4,5,6,7,7a-hexahydroisoindolin-2-yl)-4-oxobutanoate 

Relevant articles and documents

-

-

LOX INHIBITORS

The disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, Formula (I) as defined herein. Compounds according to Formula I are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.

Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use therefor for effectively treating and/or preventing FGFR-related diseases such as tumors

The present invention relates to an alkynyl-substituted heterocyclic compound serving as an FGFR inhibitor, a preparation method therefor and a medical use therefor. In particular, the present invention relates to a compound represented by the general formula (I) and its pharmaceutically acceptable salt, a pharmaceutical composition including the compound or its pharmaceutically acceptable salt, a method for treating and/or preventing FGFR-related diseases, particularly tumors, by using the compound or its pharmaceutically acceptable salt, and a preparation method of the compound or its pharmaceutically acceptable salt. The present invention also relates to an use of the compound or its pharmaceutically acceptable salt, or an pharmaceutical composition including the compound or its pharmaceutically acceptable salt in the preparation of a drug for treating and/or preventing FGFR-related diseases, particularly tumors, wherein the definition of each substituent in the general formula (I) is the same as that in the specification.

Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor

The N-Methyl-d-Aspartate receptor (NMDAR) is involved in many neurological and psychiatric disorders including Alzheimer's disease and schizophrenia. The aim of this study was to develop a positron emission tomography (PET) ligand to assess the bio-availa